


RECEIVED
CENTRAL FAX CENTER

SEP 25 2006

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound represented by the structural formula (I):



or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I),
wherein in Formula (I) above:

X, Y and Z can be the same or different and each is independently selected from the group consisting of $-\text{CH}_2-$, $-\text{CH}(\text{alkyl})-$ and $-\text{C}(\text{alkyl})_2-$;

Q^1 and Q^2 can be the same or different and each is independently selected from the group consisting of H, $-\text{G}_1-(\text{C}_{01}-\text{C}_{30} \text{ alkylene})-\text{G}$, $-\text{OR}^6$, $-\text{OC}(\text{O})\text{R}^6$, $-\text{OC}(\text{O})\text{OR}^9$, $-\text{OC}(\text{O})\text{NR}^6\text{R}^7$ and $-\text{L}-\text{M}$;

Q^3 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, $-\text{G}$, $-(\text{C}_1-\text{C}_{30} \text{ alkylene})-\text{G}$, $-\text{OR}^6$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{OR}^6$, $-\text{C}(\text{O})\text{R}^6$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{R}^6$, $-\text{C}(\text{O})\text{OR}^6$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{OR}^6$, $-\text{OC}(\text{O})\text{R}^6$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{OC}(\text{O})\text{R}^6$, $-\text{OC}(\text{O})\text{OR}^9$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{OC}(\text{O})\text{OR}^9$, $-\text{CH}=\text{CH}-\text{C}(\text{O})\text{R}^6$, $-\text{CH}=\text{CH}-\text{C}(\text{O})\text{OR}^6$, $-\text{C}\equiv\text{C}-\text{C}(\text{O})\text{OR}^6$, $-\text{C}\equiv\text{C}-\text{C}(\text{O})\text{R}^6$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{OR}^6$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{R}^6$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{OR}^6$, $-\text{CN}$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{NR}^6\text{R}^7$, $-\text{O}-\text{C}(\text{O})\text{NR}^6\text{NR}^7\text{C}(\text{O})\text{OR}^6$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{NR}^6\text{NR}^7\text{C}(\text{O})\text{OR}^6$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})(\text{aryl})-\text{N}_3$, $-\text{OC}(\text{O})-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{OR}^6$, $-\text{C}(\text{O})\text{NR}^6\text{R}^7$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{NR}^6\text{R}^7$, $-\text{OC}(\text{O})\text{NR}^6\text{R}^7$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{OC}(\text{O})\text{NR}^6\text{R}^7$, $-\text{NO}_2$, $-\text{NR}^6\text{R}^7$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{NR}^6\text{R}^7$,

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01

-O-(C₂-C₁₀ alkylene)-NR⁶R⁷, -NR⁶C(O)R⁷, -NR⁶C(O)OR⁹,
-NR⁶C(O)NR⁷R⁸, -NR⁶S(O)₀₋₂R⁹, -N(S(O)₀₋₂R⁹)₂, -CHNOR⁶, -C(O)NR⁶R⁷,
-C(O)NR⁶NR⁶R⁷, -S(O)₀₋₂NR⁶R⁷, -S(O)₀₋₂R⁹, -O-C(O)-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷,
-OC(O)-(C₁-C₁₀ alkylene)-NR⁶C(O)O-(alkylaryl), -P(O)(OR¹⁰)₂,
-(C₁-C₁₀ alkylene)-OSi(alkyl)₃, -CF₃, -OCF₃, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy,
alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl,
aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy,
heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl,
heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;

Q⁴ is 1 to 5 substituents independently selected from the group consisting of alkyl,
alkenyl, alkynyl, -G, -(C₁-C₃₀ alkylene)-G, -OR⁶, -(C₁-C₁₀ alkylene)-OR⁶, -C(O)R⁶,
-(C₁-C₁₀ alkylene)-C(O)R⁶, -C(O)OR⁶, -(C₁-C₁₀ alkylene)-C(O)OR⁶, -OC(O)R⁶,
-(C₁-C₁₀ alkylene)-OC(O)R⁶, -OC(O)OR⁹, -(C₁-C₁₀ alkylene)-OC(O)OR⁹, -CH=CH-C(O)R⁶,
-CH=CH-C(O)OR⁶, -C≡C-C(O)OR⁶, -C≡C-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-OR⁶,
-O-(C₁-C₁₀ alkylene)-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-C(O)OR⁶, -CN,
-O-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -O-C(O)NR⁶NR⁷C(O)OR⁶,
-O-(C₁-C₁₀ alkylene)-C(O)NR⁶NR⁷C(O)OR⁶, -O-(C₁-C₁₀ alkylene)-C(O)(aryl)-N₃,
-OC(O)-(C₁-C₁₀ alkylene)-C(O)OR⁶, -C(O)NR⁶R⁷, -(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷,
-OC(O)NR⁶R⁷, -(C₁-C₁₀ alkylene)-OC(O)NR⁶R⁷, -NO₂, -NR⁶R⁷, -(C₁-C₁₀ alkylene)-NR⁶R⁷,
-O-(C₂-C₁₀ alkylene)-NR⁶R⁷, -NR⁶C(O)R⁷, -NR⁶C(O)OR⁹, -NR⁶C(O)NR⁷R⁸, -NR⁶S(O)₀₋₂R⁹,
-N(S(O)₀₋₂R⁹)₂, -CHNOR⁶, -C(O)NR⁶R⁷, -C(O)NR⁶NR⁶R⁷, -S(O)₀₋₂NR⁶R⁷, -S(O)₀₋₂R⁹,
-O-C(O)-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -OC(O)-(C₁-C₁₀ alkylene)-NR⁶C(O)O-(alkylaryl),
-P(O)(OR¹⁰)₂, -(C₁-C₁₀ alkylene)-OSi(alkyl)₃, -CF₃, -OCF₃, halo, alkoxyalkoxy,
alkoxyalkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkylidioyl,
allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl,

(W0301915.1)

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01

benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;

Q^5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -G, $-(C_1-C_{30} \text{ alkylene})-G$, $-OR^6$, $-(C_1-C_{10} \text{ alkylene})-OR^6$, $-C(O)R^6$, $-(C_1-C_{10} \text{ alkylene})-C(O)R^6$, $-C(O)OR^6$, $-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, $-OC(O)R^6$, $-(C_1-C_{10} \text{ alkylene})-OC(O)R^6$, $-OC(O)OR^6$, $-(C_1-C_{10} \text{ alkylene})-OC(O)OR^6$, $-CH=CH-C(O)R^6$, $-CH=CH-C(O)OR^6$, $-C\equiv C-C(O)OR^6$, $-C\equiv C-C(O)R^6$, $-O-(C_1-C_{10} \text{ alkylene})-OR^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)R^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, -CN, $-O-(C_1-C_{10} \text{ alkylene})-C(O)NR^6R^7$, $-O-C(O)NR^6NR^7C(O)OR^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)NR^6NR^7C(O)OR^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)(\text{aryl})-N_3$, $-OC(O)-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, $-C(O)NR^6R^7$, $-(C_1-C_{10} \text{ alkylene})-C(O)NR^6R^7$, $-OC(O)NR^6R^7$, $-(C_1-C_{10} \text{ alkylene})-OC(O)NR^6R^7$, $-NO_2$, $-NR^6R^7$, $-(C_1-C_{10} \text{ alkylene})-NR^6R^7$, $-O-(C_2-C_{10} \text{ alkylene})-NR^6R^7$, $-NR^6C(O)R^7$, $-NR^6C(O)OR^9$, $-NR^6C(O)NR^7R^8$, $-NR^6S(O)_{0.2}R^9$, $-N(S(O)_{0.2}R^9)_2$, $-CHNOR^6$, $-C(O)NR^6R^7$, $-C(O)NR^6NR^6R^7$, $-S(O)_{0.2}NR^6R^7$, $-S(O)_{0.2}R^9$, $-O-C(O)-(C_1-C_{10} \text{ alkylene})-C(O)NR^6R^7$, $-OC(O)-(C_1-C_{10} \text{ alkylene})-NR^6C(O)O-(\text{alkylaryl})$, $-P(O)(OR^{10})_2$, $-(C_1-C_{10} \text{ alkylene})-OSi(\text{alkyl})_3$, $-CF_3$, $-OCF_3$, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyaryalkoxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxyalkoxy, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;


wherein optionally one or more carbon atoms of the $-(C_1-C_{30} \text{ alkylene})$ - radical of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is independently replaced by -O-, $-C(O)-$, $-CH=CH-$, $-C\equiv C-$, $-N(\text{alkyl})-$, $-N(\text{alkylaryl})-$ or $-NH-$;

G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue

Reply under **37 CFR 1.116**
 Expedited Procedure
 Technology Center 1624
 Attorney Docket No. CV06038US01


comprising 2 to 9 amino acids, trialkylammoniumalkyl ~~saltradiol~~ and $-S(O)_2-OH$, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with $-L-M$;

L is selected from the group consisting of




wherein Me is methyl;


M is selected from the group of moieties consisting of




Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01




(M3),




(M4),



(M5),




(M6),



(M7),

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01



pharmaceutically acceptable salts of the moieties (M1) to (M9) and free acids of the moieties (M1) to (M9);

R^2 and R^3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;

R^6 , R^7 and R^8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and

each R^9 is independently alkyl, aryl or arylalkyl.

each R^{10} is independently H or alkyl;

q is 0 or 1;

r is 0 or 1;

m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;

x1 is 1 to 10;

x2 is 1 to 10;

x3 is 1 to 10;

x4 is 1 to 10;

x5 is 1 to 10;

x6 is 1 to 10; and

x7 is 1 to 10;

x8 is 1 to 10;

{W0301915.1}

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01

x9 is 1 to 10;

x10 is 1 to 10; and

x11 is 1 to 10;

with the proviso that at least one of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is -L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with -L-M, and wherein each of the above alkyl, alkenyl, alkynyl, alkylene, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyacetylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, or heterocyclylcarbonylalkoxy groups, when present, is independently substituted or unsubstituted.

2. (Original) The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is $-\text{CH}_2-$.

3. (Original) The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is $-\text{CH}_2-$, Q^1 is $-\text{OR}^6$, wherein R^6 is hydrogen and Q^5 is fluorine.

4. (Previously Presented) The compound according to claim 1, wherein R^2 and R^3 are each hydrogen.

5. (Original) The compound according to claim 1, wherein Q^1 and Q^2 are each independently selected from the group consisting of $-\text{OR}^6$, $-\text{O}(\text{CO})\text{R}^6$, $-\text{O}(\text{CO})\text{OR}^9$ and $-\text{O}(\text{CO})\text{NR}^6\text{R}^7$.

6. (Original) The compound according to claim 1, wherein Q^4 is halo or $-\text{OR}^6$.

{W0301915.1}


Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01

7. (Original) The compound according to claim 1, wherein Q^1 is $-OR^6$ wherein R^6 is H.

8. (Original) The compound according to claim 1, wherein Q^1, Q^2, Q^3, Q^4 or Q^5 is $-L-M$.

9. (Previously Presented) The compound according to claim 1, wherein Q^1, Q^2, Q^3, Q^4 or Q^5 is $-G$ or $-(C_1-C_{30} \text{ alkylene})-G$.

10. (Withdrawn) The compound according to claim 1, wherein G is selected from the group consisting of:



wherein R, R^a and R^b can be the same or different and each is independently selected from the group consisting of H, $-OH$, halo, $-NH_2$, azido, alkoxyalkoxy or $-W-R^{30}$;

W is independently selected from the group consisting of $-NH-C(O)-$, $-O-C(O)-$, $-O-C(O)-N(R^{31})-$, $-NH-C(O)-N(R^{31})-$ and $-O-C(S)-N(R^{31})-$;

R^{2a} and R^{6a} can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, aryl and arylalkyl;

$R^{3a}, R^{4a}, R^{5a}, R^{7a}, R^{3b}$ and R^{4b} can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, arylalkyl, $-C(O)alkyl$ and $-C(O)aryl$;

(W0301915.1)

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01


R^{30} is independently selected from the group consisting of R^{32} -substituted T, R^{32} -substituted-T-alkyl, R^{32} -substituted-alkenyl, R^{32} -substituted-alkyl, R^{32} -substituted-cycloalkyl and R^{32} -substituted-cycloalkylalkyl;

R^{31} is independently selected from the group consisting of H and alkyl;


T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;

R^{32} is 1 to 3 substituents which are each independently selected from the group consisting of H, halo, alkyl, -OH, phenoxy, -CF₃, -NO₂, alkoxy, methylenedioxy, oxo, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -N(CH₃)₂, -C(O)-NHalkyl, -C(O)-N(alkyl)₂, -C(O)-alkyl, -C(O)-alkoxy and pyrrolidinylcarbonyl; or R^{32} is a covalent bond and R^{31} , the nitrogen to which it is attached and R^{32} form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a alkoxy carbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group.

11. (Withdrawn) The compound according to claim 10, wherein G is selected from:




Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01




wherein Ac is acetyl and Ph is phenyl.

12. (Previously Presented) The compound according to claim 1, wherein optionally one or more carbon atoms of the $-(C_1-C_{30} \text{ alkylene})-$ radical of Q¹, Q², Q³, Q⁴ and Q⁵ is independently replaced by $-O-$.

13. (Original) The compound according to claim 1, wherein L is




14. (Original) The compound according to claim 1, wherein L is




Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01

15. (Original) The compound according to claim 1, wherein M is




(M1) or pharmaceutically acceptable salts thereof.

- 16 (Original) The compound according to claim 1, wherein M is



(M2) or pharmaceutically acceptable salts thereof.

17. (Original) The compound according to claim 1, wherein M is




(M3) or pharmaceutically acceptable salts thereof.


{W0301915.1}

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01


18. (Original) The compound according to claim 1, wherein M is




19. (Original) The compound according to claim 1, wherein M is



20. (Original) The compound according to claim 1, which is selected from the group consisting of




Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01




16

(III),



18

(IV) and



20

(V).

21. (Currently Amended) A pharmaceutical composition for the treatment of atherosclerosis, hypercholesterolemia, sitosterolemia, ~~diabetes mellitus, obesity, stroke,~~ lowering a concentration of cholesterol, phytosterol or 5 α -stanol in plasma of a ~~mammal, treating demyelination or treating Alzheimer's disease and/or regulating levels of amyloid β peptides in a~~ subject comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.

22. (Original) A pharmaceutical composition comprising a cholesterol-lowering effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.

(W0301915.1)

14

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06038US01

23. (Currently Amended) A method of treating atherosclerosis, hypercholesterolemia, sitosterolemia, ~~diabetes mellitus, obesity, stroke,~~ lowering a concentration of cholesterol, phytosterol or 5 α -stanol in plasma of a ~~mammal, treating demyelination or treating Alzheimer's disease or regulating a level of an amyloid β peptide in a~~ subject comprising the step of administering to a subject in need of such treatment an effective amount of a compound of claim 1.

24. (Original) A method of lowering cholesterol level in plasma of a mammal in need of such treatment comprising administering a pharmaceutically effective amount of the compound of claim 1.